SGMO

MKT CAP:$75M

Sangamo Therapeutics, Inc.

Market Cap

$75M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.25-$0.19 (-43.87%)

Apr 24, 2026

Company Details

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome r...

CEO

Alexander D. Macrae Ch.B

IPO Date

Apr 6, 2000

Website

www.sangamo.com

Key Metrics TTM

Revenue

$40M

-31.6% YoY

Net Income

-$123M

EPS (Diluted)

-$0.44

Free Cash Flow

-$97M

Revenue / Share

$0.12

Gross Margin

80.8%

Operating Margin

-273.1%

Net Margin

-310.8%

FCF Margin

-246.0%

P/S

1.9x

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 30, 2026

$40M-31.6%EPS -$0.44

Q4 2025

Mar 30, 2026

$14M+88.4%EPS -$0.11

Q3 2025

Nov 6, 2025

$581.0K-98.8%EPS -$0.11

Q2 2025

Aug 7, 2025

$18M+5042.1%EPS -$0.08

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$28M	-$30M	-$45M
Q2 22	$29M	-$31M	-$46M
Q3 22	$26M	-$39M	-$55M
Q4 22	$27M	-$39M	-$55M
Q1 23	$158M	$95M	$18M
Q2 23	$7M	-$52M	-$124M
Q3 23	$9M	-$48M	-$106M
Q4 23	$2M	$2M	-$62M
Q1 24	$481.0K	$481.0K	-$52M
Q2 24	$356.0K	$356.0K	-$37M
Q3 24	$49M	$49M	$11M
Q4 24	$8M	$8M	-$26M
Q1 25	$6M	$6M	-$30M
Q2 25	$18M	$18M	-$18M
Q3 25	$581.0K	$581.0K	-$36M
Q4 25	$14M	$7M	-$25M

Valuation

Quarter	P/S	P/E
Q1 22	7.4x	—
Q2 22	5.5x	—
Q3 22	7.0x	—
Q4 22	4.8x	—
Q1 23	1.3x	—
Q2 23	1.1x	—
Q3 23	0.5x	—
Q4 23	0.5x	—
Q1 24	6.6x	—
Q2 24	5.6x	—
Q3 24	3.5x	—
Q4 24	8.5x	—
Q1 25	2.3x	—
Q2 25	1.5x	—
Q3 25	5.5x	—
Q4 25	2.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$59M	-$62M
Q2 22	-$54M	-$59M
Q3 22	-$54M	-$58M
Q4 22	-$57M	-$65M
Q1 23	-$66M	-$77M
Q2 23	-$61M	-$66M
Q3 23	-$47M	-$50M
Q4 23	-$51M	-$53M
Q1 24	-$49M	-$49M
Q2 24	-$27M	-$27M
Q3 24	$12M	$12M
Q4 24	-$3M	-$4M
Q1 25	-$26M	-$26M
Q2 25	-$18M	-$18M
Q3 25	-$28M	-$29M
Q4 25	-$24M	-$24M

Capital Expenditures

Quarter	CapEx
Q1 22	$3M
Q2 22	$5M
Q3 22	$4M
Q4 22	$7M
Q1 23	$10M
Q2 23	$6M
Q3 23	$3M
Q4 23	$3M
Q1 24	$0
Q2 24	$0
Q3 24	$115.0K
Q4 24	$152.0K
Q1 25	$0
Q2 25	$24.0K
Q3 25	$64.0K
Q4 25	$14.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+7.4%	+1.3%
Q2 22	+5.4%	-1.9%
Q3 22	-7.4%	+5.7%
Q4 22	-2.7%	+21.7%
Q1 23	+459.5%	+90.4%
Q2 23	-76.7%	+73.6%
Q3 23	-64.5%	+42.3%
Q4 23	-92.5%	-22.4%
Q1 24	-99.7%	-62.8%
Q2 24	-94.8%	-71.3%
Q3 24	+425.8%	-66.5%
Q4 24	+269.8%	-47.7%
Q1 25	+1238.3%	-30.7%
Q2 25	+5042.1%	-3.4%
Q3 25	-98.8%	-6.8%
Q4 25	+88.4%	+16.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	0.0%
Q2 22	$8M	27.0%
Q3 22	$8M	29.5%
Q4 22	$8M	30.3%
Q1 23	$8M	5.2%
Q2 23	$7M	99.3%
Q3 23	$6M	65.9%
Q4 23	$6M	299.1%
Q1 24	$3M	565.3%
Q2 24	$3M	861.0%
Q3 24	$3M	6.7%
Q4 24	$3M	43.5%
Q1 25	$3M	40.3%
Q2 25	$2M	12.2%
Q3 25	$2M	366.1%
Q4 25	$2M	15.0%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$59M	$15M
Q2 22	$60M	$15M
Q3 22	$65M	$16M
Q4 22	$66M	$16M
Q1 23	$63M	$18M
Q2 23	$63M	$15M
Q3 23	$57M	$14M
Q4 23	$51M	$13M
Q1 24	$36M	$12M
Q2 24	$24M	$12M
Q3 24	$28M	$11M
Q4 24	$24M	$10M
Q1 25	$26M	$10M
Q2 25	$27M	$9M
Q3 25	$28M	$8M
Q4 25	$31M	$8M

Revenue Segments

Quarter	License	Service	Reportable Segment
Q1 24	$481.0K	—	—
Q2 24	$356.0K	—	—
Q3 24	$49M	$547.0K	—
Q2 25	$18M	—	—
Q3 25	—	—	$581.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$120M	$198M	$318M
Q2 22	$118M	$198M	$316M
Q3 22	$95M	$219M	$314M
Q4 22	$100M	$177M	$278M
Q1 23	$78M	$127M	$205M
Q2 23	$67M	$76M	$143M
Q3 23	$57M	$76M	$132M
Q4 23	$45M	$36M	$81M
Q1 24	$54M	$0	$54M
Q2 24	$28M	$0	$28M
Q3 24	$39M	$0	$39M
Q4 24	$42M	$0	$42M
Q1 25	$25M	$0	$25M
Q2 25	$38M	$0	$38M
Q3 25	$31M	$0	$31M
Q4 25	$21M	$0	$21M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	146M	+0.3%	+2.2%
Q2 22	148M	+1.3%	+2.9%
Q3 22	158M	+6.7%	+8.7%
Q4 22	165M	+4.2%	+13.0%
Q1 23	169M	+2.7%	+15.7%
Q2 23	174M	+3.0%	+17.7%
Q3 23	177M	+1.6%	+12.1%
Q4 23	178M	+0.3%	+7.8%
Q1 24	180M	+1.5%	+6.6%
Q2 24	204M	+13.1%	+17.0%
Q3 24	214M	+5.1%	+21.0%
Q4 24	210M	-1.9%	+18.3%
Q1 25	220M	+4.8%	+22.1%
Q2 25	257M	+16.7%	+26.0%
Q3 25	304M	+18.4%	+42.0%
Q4 25	338M	+11.0%	+60.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$65.5K	431
Q2 22	$68.2K	431
Q3 22	$61.4K	431
Q4 22	$57.0K	478
Q1 23	$330.5K	478
Q2 23	$14.3K	478
Q3 23	$19.7K	478
Q4 23	$5.0K	405
Q1 24	$1.2K	405
Q2 24	$879	405
Q3 24	$122.0K	405
Q4 24	$41.3K	183
Q1 25	$35.2K	183
Q2 25	$100.0K	183
Q3 25	$3.2K	183
Q4 25	$100.2K	142

Revenue / Employee